Search company, investor...
Search
AXIM BIOTECHNOLOGIES company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aximbiotech.com

Stage

Seed | Alive

Total Raised

$600K

Last Raised

$600K | 4 yrs ago

Revenue

$0000 

Mosaic Score

+90 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About AXIM BIOTECHNOLOGIES

AXIM Biotechnologies is a biotechnology company focusing on research, development, and production of pharmaceutical, nutraceutical, and cosmetic products as well as alternative energy sources. It prioritizes well-being of its customers while embracing a solid fiscal strategy.

AXIM BIOTECHNOLOGIES Headquarters Location

45 Rockefeller Plaza 20th Floor

New York, New York, 10111,

United States

844-294-6246

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AXIM BIOTECHNOLOGIES

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AXIM BIOTECHNOLOGIES is included in 2 Expert Collections, including Cannabis.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

AXIM BIOTECHNOLOGIES Patents

AXIM BIOTECHNOLOGIES has filed 25 patents.

The 3 most popular patent topics include:

  • Cannabinoids
  • Designer drugs
  • Phenols
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/28/2020

8/17/2021

Cannabinoids, Designer drugs, Phenols, Benzochromenes, Euphoriants

Grant

Application Date

1/28/2020

Grant Date

8/17/2021

Title

Related Topics

Cannabinoids, Designer drugs, Phenols, Benzochromenes, Euphoriants

Status

Grant

Latest AXIM BIOTECHNOLOGIES News

AXIM Biotechnologies : Statement of Changes in Beneficial Ownership - Form 4

Sep 23, 2022

09/19 09/19 09/23/2022 | 04:45pm EDT Message : FORM 4 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL 1. Relationship of Reporting Person(s) to Issuer (Check all applicable) 3. Date of Earliest Transaction (Month/Day/Year) (Street) 6. Individual or Join/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) 1.Title of Security 3. Transaction Code 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct (D) or Indirect (I) 7. Nature of Indirect Beneficial Ownership Code (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivate Security 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 4. Transaction Code 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security 8. Price of Derivative Security 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 11. Nature of Indirect Beneficial Ownership Code Reporting Owners (**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). (1) Reporting Person acquired an option to purchase up to 500,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may purchased at the date which is six (6) months following the grant date. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. Attachments

AXIM BIOTECHNOLOGIES Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AXIM BIOTECHNOLOGIES Rank

  • Where is AXIM BIOTECHNOLOGIES's headquarters?

    AXIM BIOTECHNOLOGIES's headquarters is located at 45 Rockefeller Plaza, New York.

  • What is AXIM BIOTECHNOLOGIES's latest funding round?

    AXIM BIOTECHNOLOGIES's latest funding round is Seed.

  • How much did AXIM BIOTECHNOLOGIES raise?

    AXIM BIOTECHNOLOGIES raised a total of $600K.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.